Last reviewed · How we verify
Ketamine Injectable Product
Ketamine Injectable Product is a NMDA receptor antagonist Small molecule drug developed by Hackensack Meridian Health. It is currently FDA-approved for Induction and maintenance of anesthesia, Analgesia and sedation, Treatment-resistant depression (off-label/emerging indication). Also known as: Ketalar, Ketalar Hydrocholoride.
Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks glutamate signaling in the central nervous system.
Ketamine is a small molecule medication used to treat various conditions, including asthma exacerbations, pain, and analgesia. It is administered through nebulization, typically at a dose of 0.5 mg/kg in normal saline, or through other methods such as ultrasound-guided facia iliaca block.
At a glance
| Generic name | Ketamine Injectable Product |
|---|---|
| Also known as | Ketalar, Ketalar Hydrocholoride |
| Sponsor | Hackensack Meridian Health |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia, Pain Management, Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Ketamine binds to the phencyclidine binding site within the NMDA receptor ion channel, blocking the flow of ions and preventing excitatory neurotransmission. This mechanism produces rapid-onset anesthetic and analgesic effects, and at sub-anesthetic doses, it has been shown to produce rapid antidepressant effects through modulation of glutamatergic and other neurotransmitter systems.
Approved indications
- Induction and maintenance of anesthesia
- Analgesia and sedation
- Treatment-resistant depression (off-label/emerging indication)
Common side effects
- Dissociation
- Dizziness
- Nausea
- Increased blood pressure
- Hallucinations
- Emergence reactions
Key clinical trials
- Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine (PHASE3)
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (PHASE4)
- Optimal Timing of Ketamine Initiation for SCD Pain (PHASE3)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room (PHASE3)
- The Efface of Lidocaine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy (PHASE1)
- The Efface of Ketamine vs. Lidocaine in the Management of Pain After Laparoscopic Cholecystectomy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketamine Injectable Product CI brief — competitive landscape report
- Ketamine Injectable Product updates RSS · CI watch RSS
- Hackensack Meridian Health portfolio CI
Frequently asked questions about Ketamine Injectable Product
What is Ketamine Injectable Product?
How does Ketamine Injectable Product work?
What is Ketamine Injectable Product used for?
Who makes Ketamine Injectable Product?
Is Ketamine Injectable Product also known as anything else?
What drug class is Ketamine Injectable Product in?
What development phase is Ketamine Injectable Product in?
What are the side effects of Ketamine Injectable Product?
What does Ketamine Injectable Product target?
Related
- Drug class: All NMDA receptor antagonist drugs
- Target: All drugs targeting NMDA receptor
- Manufacturer: Hackensack Meridian Health — full pipeline
- Therapeutic area: All drugs in Anesthesia, Pain Management, Psychiatry
- Indication: Drugs for Induction and maintenance of anesthesia
- Indication: Drugs for Analgesia and sedation
- Indication: Drugs for Treatment-resistant depression (off-label/emerging indication)
- Also known as: Ketalar, Ketalar Hydrocholoride
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing